Lexicon Pharmaceuticals Reports 3rd Quarter Financial Results And Discusses Collaboration With Sanofi For Sotagliflozin

Conference Call and Webcast TODAY, November 6, at 8:00 a.m. Eastern Time

THE WOODLANDS, Texas, Nov. 6, 2015 -- Lexicon Pharmaceuticals, Inc. (LXRX), today reported financial results for the third quarter ended September 30, 2015 and provided an overview of key milestones for the company's lead drug candidates.

Earlier today, Lexicon announced that it entered into a collaboration and license agreement with Sanofi for the worldwide development and commercialization of sotagliflozin.  Under the terms of the agreement, Lexicon will receive an upfront payment of $300 million and is eligible to receive development, regulatory and sales milestone payments of up to $1.4 billion.  Lexicon is also entitled to tiered, escalating royalties on net sales of sotagliflozin.  The financial results reported in this press release are as of September 30, 2015 and do not reflect any impact of this collaboration.

EyeGate Announces Interim Data From Phase 1b / 2a Clinical Trial of Iontophoretic EGP-437 Ophthalmic Solution in Macular Edema Patients

WALTHAM, Mass., Nov. 5, 2015  -- Eyegate Pharmaceuticals, Inc. (EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced interim data on the effects of iontophoretic delivery of their EGP-437 ophthalmic solution on Macular Edema patients.

"Overall, the interim data from this pilot trial suggests that iontophoresis can non-invasively deliver EGP-437 to the back of the eye. The non-invasive delivery of EGP-437 has demonstrated a positive response in some patients with macular edema. We believe that this data is encouraging, and warrants an extension to the trial to continue to work on the ideal dose and dosing regimen for the iontophoretic delivery of EGP-437," said Dr. Jeffrey Heier, M.D., Director of Vitreoretinal Service and Retina Research at Ophthalmic Consultants of Boston and the principal investigator of the trial.

Shire to Acquire Dyax Corp, Expanding and Extending Industry-Leading Hereditary Angioedema (HAE) Portfolio

Lead pipeline product, DX-2930, is a Phase 3-ready asset, offering potentially transformative prophylactic therapy for HAE

DUBLIN and BURLINGTON, Massachusetts, November 2, 2015

• DX-2930 has potential to expand HAE-treated patients and achieve annual worldwide sales of up to $2 billion with exclusivity beyond 2030

• DX-2930 is supported by proof-of-concept Phase 1B data, demonstrating a >90% reduction in HAE attacks compared to placebo in the 300mg/400mg arms in patients with > 2 attacks in the 3 months prior to study entry

• Acquisition furthers Shire's strategy to become a leading global biotech 
  

  Published: 02 November 2015

  Written by Editor

  Nasdaq   M & A   Up on News  

  Read more: Dyax Corp ( DYAX )